ClinicalTrials.gg
Active, not recruitingNCT02088554PERIGONUpdated Apr 29, 2026Results posted

PERIGON Pivotal Trial

An interventional study of Model 400 aortic valve bioprosthesis in Aortic Stenosis, sponsored by Medtronic Cardiac Surgery. Active, not recruiting at 38 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-29.

Sponsored by Medtronic Cardiac Surgery (part of Medtronic) · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,312
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 34 studies in Aortic Valve Stenosis by Medtronic — 1 open to participants now, 6 under way, none of them phase 3. Aortic Valve Stenosis · Medtronic.

Enrollment
5th of 20
1,312 · median 109
Started
2014
with 3 others
No phase
20 of 34
none open now
Registered
19th of 34
by date

Among the 34 studies in Aortic Valve Stenosis by Medtronic, this one is the 5th largest by enrollment of the 20 interventional ones that give a count, is one of 4 that started in 2014, is one of 20 with no phase, and was the 19th registered.

Aortic Valve Stenosis

1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.

Browse Aortic Valve Stenosis studies →

Open to participants now

1 of the 34 studies in Aortic Valve Stenosis by Medtronic is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Aortic Valve Stenosis by Medtronic, or all of them as a file.
02

Study summary

To evaluate the safety and effectiveness of the Model 400 aortic valve bioprosthesis.

Read the detailed description

This is a prospective, interventional, non-randomized, worldwide, multi-center trial. A maximum of 1300 subjects were to be implanted at a maximum of 40 sites in the US, Europe and Canada. The trial includes male and female patients of legal age to provide informed consent in the country where they enrolled in the trial, requiring replacement for a diseased, damaged, or malfunctioning native or prosthetic aortic valve. Subjects are followed out to 5 years, and select sites follow subjects out to 12 years. Enrollment closed on 14Jul2017 for all valve sizes. Enrollment was reopened in Apr2019 for the 29mm valve size at a subset of US and Canadian sites to obtain greater patient numbers required by the FDA to support US commercial approval of this valve size. Enrollment for the 29mm valve size closed on 14Feb2023.

03

Conditions studied

  • Aortic Stenosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient has moderate or greater aortic stenosis or regurgitation, and there is clinical indication for replacement of their native or prosthetic aortic valve with a bioprosthesis, with or without concomitant procedures, which are limited to any of the following:

    i. Left atrial appendage (LAA) ligation ii. CABG (coronary artery bypass grafting) iii. Patent foramen ovale (PFO) closure iv. Ascending aortic aneurysm or dissection repair not requiring circulatory arrest v. Resection of a sub-aortic membrane not requiring myectomy

  2. Patient is geographically stable and willing to return to the implanting site for all follow-up visits
  3. Patient is of legal age to provide in the country where they enroll in the trial
  4. Patient has been adequately informed of risks and requirements of the trial and is willing and able to provide informed consent for participation in the clinical trial

Exclusion criteria

Exclusion Criteria:

  1. Patient has a pre-existing prosthetic valve or annuloplasty device in another position or requires replacement or repair of the mitral, pulmonary or tricuspid valve
  2. Patient has had previous implant and then explant of the Model 400 aortic valve bioprosthesis
  3. Patient presents with active endocarditis, active myocarditis or other systemic infection
  4. Patient has an anatomical abnormality which would increase surgical risk of morbidity or mortality, including:

    • Ascending aortic aneurysm or dissection repair requiring circulatory arrest
    • Acute Type A aortic dissection
    • Ventricular aneurysm
    • Porcelain aorta
    • Hostile mediastinum
    • Hypertrophic obstructive cardiomyopathy (HOCM)
    • Documented pulmonary hypertension (systolic >60mmHg)
  5. Patient has a non-cardiac major or progressive disease, with a of less than 2 years. These conditions include, but are not limited to:

    • Class C liver disease
    • Terminal cancer
    • End-stage lung disease
  6. Patient has renal failure, defined as dialysis therapy or (GFR)\<30 mL/min/1.73 m2
  7. Patient has hyperparathyroidism
  8. Patient is participating in another device or drug trial or observational competitive study
  9. Patient is pregnant, lactating or planning to become pregnant during the trial period
  10. Patient has a documented history of substance (drug or alcohol) abuse
  11. Patient has greater than mild mitral valve regurgitation or greater than mild tricuspid valve regurgitation as assessed by echocardiography
  12. Patient has systolic (EF)\<20% as assessed by echocardiography
  13. Patient has Grade IV Diastolic Dysfunction
  14. Patient has documented bleeding diatheses
  15. Patient has had an acute preoperative neurological deficit or myocardial infarction and has not returned to baseline or stabilized ≥30 days prior to enrollment
  16. Patient requires emergency surgery
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,312 participants (actual)

Study arms

  • Experimental
    Model 400 aortic valve bioprosthesis

    Device: Model 400 aortic valve bioprosthesis

Interventions

  • DeviceModel 400 aortic valve bioprosthesis
06

What researchers measure

Primary outcomes

  1. Evaluate the Safety of the Model 400 Avalus Valve With Regard to Valve-related Adverse Events and Death at 1 Year Post-implant

    Safety of the valve is evaluated by the time-related incidence of valve-related adverse events and death. The following valve-related adverse events are evaluated in this study: Thromboembolism, Thrombosis, Hemorrhage, Paravalvular leak (PVL), Endocarditis, Hemolysis, Structural valve deterioration, Non-structural dysfunction, Reintervention, Explant, and Death. A minimum of 15 participants per valve size are evaluated. The incidence rates will be used to summarize valve-related adverse events and death.

    Time frame: 1 year post-implant

  2. Confirm the Effectiveness of the Model 400 Avalus Valve With Regard to the Change of New York Heart Association (NYHA) Classification From Baseline Through 1 Year

    At each timepoint, a minimum of 15 participants per valve size evaluated for change in New York Heart Association (NYHA) functional classification from baseline to 1 year post-procedure. Measure Description: Cardiac Disease with Functional Classes (lower value is more desirable than higher value) I - No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation or shortness of breath. II - Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, shortness of breath or chest pain. III - Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, shortness of breath or chest pain. IV - Symptoms of heart failure at rest. Any physical activity causes further discomfort.

    Time frame: Discharge (up to 30 days), 3-6 months, and 1 year post-implant

  3. Confirm the Effectiveness of the Model 400 Avalus Valve With Regard to Effective Orifice Area Through 1 Year Post-procedure

    A minimum of 15 participants per valve size evaluated by transthoracic echocardiography technique and assessed by an independent core laboratory. The effective orifice area (EOA) is measured as the minimal cross-sectional area of the blood flow downstream of the aortic valve.

    Time frame: Discharge (up to 30 days), 3-6 months, 1 year post-implant

  4. Confirm the Effectiveness of the Model 400 Avalus Valve With Regard to the Effective Orifice Area Index (EOAI) Through 1 Year Post-implant

    A minimum of 15 participants per valve size evaluated by transthoracic echocardiography technique and assessed by an independent core laboratory for effective orifice area index (EOAI = EOA/BSA) Effective orifice area index is equal to the effective orifice area (EOA) in cm\^2 divided by body surface area (BSA) in m\^2. The achievement criterion for the effective orifice area index (EOAI) is defined to be ≥0.6 cm\^2/m\^2 12 months after the procedure. This criterion is in accordance with the definition of severe aortic stenosis in the American College of Cardiology (ACC) / American Heart Association (AHA) guidelines for the management of valvular heart disease.

    Time frame: Discharge (up to 30 days), 3-6 months, and 1 year post-implant

  5. Confirm the Effectiveness of the Model 400 Avalus Valve With Regard to the Peak Pressure Gradient (mmHg) From Discharge up to 1 Year

    A minimum of 15 participants per valve size evaluated by transthoracic echocardiography technique and assessed by an independent core laboratory. The peak pressure gradient is the maximum value measured of flow of blood through the aortic valve as measured in millimeters of mercury.

    Time frame: Measured at discharge (up to 30 days), 3-6 months, and 1 year post-implant

  6. Confirm the Effectiveness of the Model 400 Avalus Valve With Regard to Mean Pressure Gradient (mmHg) Through 1 Year Post-implant

    A minimum of 15 participants per valve size evaluated by transthoracic echocardiography technique and will be assessed by an independent core laboratory. The mean pressure gradient is the average flow of blood through the aortic valve measured in millimeters of mercury.

    Time frame: Discharge (up to 30 days), 3-6 months, and 1 year post-implant

  7. Confirm the Effectiveness of the Model 400 Avalus Valve With Regard to Performance Index (L/Min) Through 1 Year Post-implant

    A minimum of 15 participants per valve size will have performance index (L/Min) measured by transthoracic echocardiography technique and will be assessed by an independent core laboratory. The performance index is the measurement of the effective orifice area divided by the native orifice area.

    Time frame: Discharge (up to 30 days), 3-6 months, and 1 year post-implant

  8. Confirm the Effectiveness of the Model 400 Avalus Valve With Regard to Cardiac Output (L/Min) Through 1 Year Post-implant

    Cardiac output is the amount of blood pumped by the heart per minute. A minimum of 15 participants per valve size were evaluated for this outcome measure by transthoracic echocardiography technique and assessed by an independent core laboratory.

    Time frame: Discharge (up to 30 days), 3-6 months, and 1 year post-implant

  9. Confirm the Effectiveness of the Model 400 Avalus Valve With Regard to Cardiac Index (L/Min/m^2) Through 1 Year Post-implant

    A minimum of 15 participants per valve size evaluated by transthoracic echocardiography technique and will be assessed by an independent core laboratory. The cardiac index is an assessment of the cardiac output based on a patient's size measured by dividing the cardiac output by the patient's body's surface area.

    Time frame: Discharge (up to 30 days), 3-6 months, and 1 year post-implant

Secondary outcomes

  1. Evaluate the Safety of the Model 400 Avalus Valve With Regard to Valve-related Adverse Events and Death Annually Through 5 Years Post-implant

    Safety of the valve is evaluated by the time-related incidence of valve-related adverse events and death. The following valve-related adverse events are evaluated in this study: Thromboembolism, Thrombosis, Hemorrhage, Paravalvular leak (PVL), Endocarditis, Hemolysis, Structural valve deterioration, Non-structural dysfunction, Reintervention, Explant, and Death. The Kaplan-Meier event rates will be used to summarize valve-related adverse events and death. The Kaplan-Meier rate and the corresponding 95% confidence interval will be presented for each visit interval.

    Time frame: Annually, at years 2, 3, 4, and 5 post-implant

  2. Confirm the Effectiveness of the Model 400 Avalus Valve With Regard to the Change of New York Heart Association (NYHA) Classification From Baseline Through 5 Years Post-implant

    At each timepoint, participants were evaluated for change in New York Heart Association (NYHA) functional classification from baseline through 5 years post-procedure. Measure Description: Cardiac Disease with Functional Classes (lower value is more desirable than higher value) I - No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation or shortness of breath. II - Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, shortness of breath or chest pain. III - Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, shortness of breath or chest pain. IV - Symptoms of heart failure at rest. Any physical activity causes further discomfort.

    Time frame: Annually, at years 2, 3, 4, and 5 post-implant

  3. Confirm the Effectiveness of the Model 400 Avalus Valve With Regard to Effective Orifice Area Through 5 Years Post-procedure

    Evaluated by transthoracic echocardiography technique and assessed by an independent core laboratory. The effective orifice area (EOA) is measured as the minimal cross-sectional area of the blood flow downstream of the aortic valve.

    Time frame: Annually, at years 2, 3, 4, and 5 post-implant

  4. Confirm the Effectiveness of the Model 400 Avalus Valve With Regard to the Effective Orifice Area Index (EOAI) Through 5 Years Post-implant

    Evaluated by transthoracic echocardiography technique and assessed by an independent core laboratory for effective orifice area index (EOAI = EOA/BSA) Effective orifice area index is equal to the effective orifice area (EOA) in cm\^2 divided by body surface area (BSA) in m\^2. The achievement criterion for the effective orifice area index (EOAI) is defined to be ≥0.6 cm\^2/m\^2 12 months after the procedure. This criterion is in accordance with the definition of severe aortic stenosis in the American College of Cardiology (ACC) / American Heart Association (AHA) guidelines for the management of valvular heart disease.

    Time frame: Annually, at years 2, 3, 4, and 5 post-implant

  5. Confirm the Effectiveness of the Model 400 Avalus Valve With Regard to the Peak Pressure Gradient (mmHg) From Discharge up to 5 Years Post-implant

    Evaluated by transthoracic echocardiography technique and assessed by an independent core laboratory. The peak pressure gradient is the maximum value measured of flow of blood through the aortic valve as measured in millimeters of mercury.

    Time frame: Annually, at years 2, 3, 4, and 5 post-implant

  6. Confirm the Effectiveness of the Model 400 Avalus Valve With Regard to Mean Pressure Gradient (mmHg) Through 5 Years Post-implant

    Evaluated by transthoracic echocardiography technique and will be assessed by an independent core laboratory. The mean pressure gradient is the average flow of blood through the aortic valve measured in millimeters of mercury.

    Time frame: Annually, at years 2, 3, 4, and 5 post-implant

  7. Confirm the Effectiveness of the Model 400 Avalus Valve With Regard to Performance Index (L/Min) Through 5 Years Post-implant

    Performance index (L/Min) measured by transthoracic echocardiography technique and will be assessed by an independent core laboratory. The performance index is the measurement of the effective orifice area divided by the native orifice area.

    Time frame: Annually, at years 2, 3, 4, and 5 post-implant

  8. Confirm the Effectiveness of the Model 400 Avalus Valve With Regard to Cardiac Output (L/Min) Through 5 Years Post-implant

    Cardiac output is the amount of blood pumped by the heart per minute, evaluated by transthoracic echocardiography technique and assessed by an independent core laboratory.

    Time frame: Annually, at years 2, 3, 4, and 5 post-implant

  9. Confirm the Effectiveness of the Model 400 Avalus Valve With Regard to Cardiac Index (L/Min/m^2) Through 5 Years Post-implant

    Evaluated by transthoracic echocardiography technique and will be assessed by an independent core laboratory. The cardiac index is an assessment of the cardiac output based on a patient's size measured by dividing the cardiac output by the patient's body's surface area.

    Time frame: Annually, at years 2, 3, 4, and 5 post-implant

Other outcomes

  1. Evaluate the Safety of the Model 400 Avalus Valve With Regard to Valve-related Adverse Events and Death at 1 Year Post-implant (Remaining Data From 29mm Valve Participants Not Required for Meeting Primary Outcomes)

    Safety of the valve is evaluated by the time-related incidence of valve-related adverse events and death. The following valve-related adverse events are evaluated in this study: Thromboembolism, Thrombosis, Hemorrhage, Paravalvular leak (PVL), Endocarditis, Hemolysis, Structural valve deterioration, Non-structural dysfunction, Reintervention, Explant, and Death. A minimum of 15 participants per valve size are evaluated. The Kaplan-Meier event rates will be used to summarize valve-related adverse events and death. The Kaplan-Meier rate and the corresponding 95% confidence interval will be presented for each visit interval.

    Time frame: 1 year post-implant

  2. Confirm the Effectiveness of the Model 400 Avalus Valve With Regard to the Change of New York Heart Association (NYHA) Classification From Baseline Through 1 Year (Remaining Data From 29mm Valve Participants Not Required for Meeting Primary Outcomes)

    Participants evaluated for change in New York Heart Association (NYHA) functional classification from baseline to 1 year post-procedure. Measure Description: Cardiac Disease with Functional Classes (lower value is more desirable than higher value) I - No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation or shortness of breath. II - Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, shortness of breath or chest pain. III - Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, shortness of breath or chest pain. IV - Symptoms of heart failure at rest. Any physical activity causes further discomfort.

    Time frame: 3-6 months and 1 year post-implant

  3. Confirm the Effectiveness of the Model 400 Avalus Valve With Regard to Effective Orifice Area Through 1 Year Post-procedure (Remaining Data From 29mm Valve Participants Not Required for Meeting Primary Outcomes)

    Evaluated by transthoracic echocardiography technique and assessed by an independent core laboratory. The effective orifice area (EOA) is measured as the minimal cross-sectional area of the blood flow downstream of the aortic valve.

    Time frame: 3-6 months, 1 year post-implant

  4. Confirm the Effectiveness of the Model 400 Avalus Valve With Regard to the Effective Orifice Area Index (EOAI) Through 1 Year Post-implant (Remaining Data From 29mm Valve Participants Not Required for Meeting Primary Outcomes)

    Evaluated by transthoracic echocardiography technique and assessed by an independent core laboratory for effective orifice area index (EOAI = EOA/BSA) Effective orifice area index is equal to the effective orifice area (EOA) in cm\^2 divided by body surface area (BSA) in m\^2. The achievement criterion for the effective orifice area index (EOAI) is defined to be ≥0.6 cm\^2/m\^2 12 months after the procedure. This criterion is in accordance with the definition of severe aortic stenosis in the American College of Cardiology (ACC) / American Heart Association (AHA) guidelines for the management of valvular heart disease.

    Time frame: 3-6 months, and 1 year post-implant

  5. Confirm the Effectiveness of the Model 400 Avalus Valve With Regard to the Peak Pressure Gradient (mmHg) From Discharge up to 1 Year (Remaining Data From 29mm Valve Participants Not Required for Meeting Primary Outcomes)

    Evaluated by transthoracic echocardiography technique and assessed by an independent core laboratory. The peak pressure gradient is the maximum value measured of flow of blood through the aortic valve as measured in millimeters of mercury.

    Time frame: 3-6 months, and 1 year post-implant

  6. Confirm the Effectiveness of the Model 400 Avalus Valve With Regard to Mean Pressure Gradient (mmHg) Through 1 Year Post-implant (Remaining Data From 29mm Valve Participants Not Required for Meeting Primary Outcomes)

    Evaluated by transthoracic echocardiography technique and will be assessed by an independent core laboratory. The mean pressure gradient is the average flow of blood through the aortic valve measured in millimeters of mercury.

    Time frame: 3-6 months, and 1 year post-implant

  7. Confirm the Effectiveness of the Model 400 Avalus Valve With Regard to Performance Index (L/Min) Through 1 Year Post-implant (Remaining Data From 29mm Valve Participants Not Required for Meeting Primary Outcomes)

    Performance index (L/Min) measured by transthoracic echocardiography technique and will be assessed by an independent core laboratory. The performance index is the measurement of the effective orifice area divided by the native orifice area.

    Time frame: 3-6 months, and 1 year post-implant

  8. Confirm the Effectiveness of the Model 400 Avalus Valve With Regard to Cardiac Output (L/Min) Through 1 Year Post-implant (Remaining Data From 29mm Valve Participants Not Required for Meeting Primary Outcomes)

    Cardiac output is the amount of blood pumped by the heart per minute. Evaluated by transthoracic echocardiography technique and assessed by an independent core laboratory.

    Time frame: 3-6 months, and 1 year post-implant

  9. Confirm the Effectiveness of the Model 400 Avalus Valve With Regard to Cardiac Index (L/Min/m^2) Through 1 Year Post-implant (Remaining Data From 29mm Valve Participants Not Required for Meeting Primary Outcomes)

    Evaluated by transthoracic echocardiography technique and will be assessed by an independent core laboratory. The cardiac index is an assessment of the cardiac output based on a patient's size measured by dividing the cardiac output by the patient's body's surface area.

    Time frame: 3-6 months, and 1 year post-implant

  10. Confirm the Effectiveness of the Model 400 Avalus Valve by Clinically Acceptable Hemodynamic Performance From Years 6 Through 12 Post-implant.

    Long-term follow-up clinically acceptable hemodynamic performance defined as freedom from surgical explant and/or percutaneous valve-in-valve reintervention due to structural valve deterioration

    Time frame: Annually, years 6-12 post-implant

  11. Confirm the Effectiveness of the Model 400 Avalus Valve From Years 6 - 12 Post-implant by Freedom From Valve-related Death

    Time frame: Annually, years 6 though 12 post-implant

  12. Confirm the Effectiveness of the Model 400 Avalus Valve From Years 6 - 12 Post-implant by Freedom From All-cause Mortality

    For time-to-event outcomes, Kaplan-Meier (actuarial) analysis of the event-free rate performed annually through twelve years.

    Time frame: Annually, years 6 though 12 post-implant

  13. Confirm the Effectiveness of the Model 400 Avalus Valve From Years 6 - 12 Post-implant by Change in NYHA Functional Classification Status From Baseline

    Time frame: Annually, years 6 though 12 post-implant

  14. Confirm the Effectiveness of the Model 400 Avalus Valve With Regard to Effective Orifice Area Through 12 Years Post-procedure

    Evaluated by transthoracic echocardiography technique and assessed by an independent core laboratory. The effective orifice area (EOA) is measured as the minimal cross-sectional area of the blood flow downstream of the aortic valve.

    Time frame: Annually, years 6 though 12 post-implant

  15. Confirm the Effectiveness of the Model 400 Avalus Valve With Regard to the Effective Orifice Area Index (EOAI) Through 12 Years Post-implant

    Evaluated by transthoracic echocardiography technique and assessed by an independent core laboratory for effective orifice area index (EOAI = EOA/BSA) Effective orifice area index is equal to the effective orifice area (EOA) in cm\^2 divided by body surface area (BSA) in m\^2. The achievement criterion for the effective orifice area index (EOAI) is defined to be ≥0.6 cm\^2/m\^2 12 months after the procedure. This criterion is in accordance with the definition of severe aortic stenosis in the American College of Cardiology (ACC) / American Heart Association (AHA) guidelines for the management of valvular heart disease.

    Time frame: Annually, years 6 though 12 post-implant

  16. Confirm the Effectiveness of the Model 400 Avalus Valve With Regard to the Peak Pressure Gradient (mmHg) up to 12 Years Post-implant

    Evaluated by transthoracic echocardiography technique and assessed by an independent core laboratory. The peak pressure gradient is the maximum value measured of flow of blood through the aortic valve as measured in millimeters of mercury.

    Time frame: Annually, years 6 though 12 post-implant

  17. Confirm the Effectiveness of the Model 400 Avalus Valve With Regard to Mean Pressure Gradient (mmHg) Through 12 Years Post-implant

    Evaluated by transthoracic echocardiography technique and will be assessed by an independent core laboratory. The mean pressure gradient is the average flow of blood through the aortic valve measured in millimeters of mercury.

    Time frame: Annually, years 6 though 12 post-implant

  18. Confirm the Effectiveness of the Model 400 Avalus Valve With Regard to Performance Index (L/Min) Through 12 Years Post-implant

    Performance index (L/Min) measured by transthoracic echocardiography technique and will be assessed by an independent core laboratory. The performance index is the measurement of the effective orifice area divided by the native orifice area.

    Time frame: Annually, years 6 though 12 post-implant

  19. Confirm the Effectiveness of the Model 400 Avalus Valve With Regard to Cardiac Output (L/Min) Through 12 Years Post-implant

    Cardiac output is the amount of blood pumped by the heart per minute. Evaluated by transthoracic echocardiography technique and assessed by an independent core laboratory.

    Time frame: Annually, years 6 though 12 post-implant

  20. Confirm the Effectiveness of the Model 400 Avalus Valve With Regard to Cardiac Index (L/Min/m^2) Through 12 Years Post-implant

    Evaluated by transthoracic echocardiography technique and will be assessed by an independent core laboratory. The cardiac index is an assessment of the cardiac output based on a patient's size measured by dividing the cardiac output by the patient's body's surface area.

    Time frame: Annually, years 6 though 12 post-implant

07

Results

Posted Jun 4, 2024

Participant flow

Participant flow — Overall Study
MilestoneMedtronic Model 400 Avalus Bioprosthetic Aortic Valve
Started1312
Implanted1132
1 year completion1050
Completed268
Not completed1044
Withdrew: Exited before procedure130
Withdrew: Attempted but not implanted31
Withdrew: Implant not attempted19
Withdrew: Pending next visit532
Withdrew: Death170
Withdrew: Subject withdrew + physician withdrew + subject not implanted with study valve96
Withdrew: Lost to follow-up23
Withdrew: Explanted32
Withdrew: Any other reason not covered by previous categories11

Outcome measures

PrimaryEvaluate the Safety of the Model 400 Avalus Valve With Regard to Valve-related Adverse Events and Death at 1 Year Post-implant

Safety of the valve is evaluated by the time-related incidence of valve-related adverse events and death. The following valve-related adverse events are evaluated in this study: Thromboembolism, Thrombosis, Hemorrhage, Paravalvular leak (PVL), Endocarditis, Hemolysis, Structural valve deterioration, Non-structural dysfunction, Reintervention, Explant, and Death. A minimum of 15 participants per valve size are evaluated. The incidence rates will be used to summarize valve-related adverse events and death.

Time frame:
1 year post-implant
Reported as:
Number · percentage of participants with event
Evaluate the Safety of the Model 400 Avalus Valve With Regard to Valve-related Adverse Events and Death at 1 Year Post-implant
percentage of participants with eventMedtronic Avalus Valve 19mmMedtronic Avalus Valve 21mmMedtronic Avalus Valve 23mmMedtronic Avalus Valve 25mmMedtronic Avalus Valve 27mmMedtronic Avalus Valve 29mmMedtronic Avalus Valve (17mm - 29mm)
All death9.52.82.22.94.03.83.0
Valve- related death0.00.90.20.00.00.00.3
Thromboembolism0.02.82.72.94.03.82.8
Valve thrombosis0.00.00.00.00.00.00.0
All hemorrhage7.13.86.74.37.90.05.4
Major hemorrhage7.10.55.03.45.00.03.6
All paravalvular leak0.00.50.50.61.00.00.5
Major paravalvular leak0.00.50.00.30.00.00.2
Endocarditis0.00.51.51.41.00.01.1
Hemolysis0.00.00.00.00.00.00.0
Non-structural valve dysfunction0.00.50.50.61.00.00.5
Structural valve deterioration0.00.00.00.00.00.00.0
Severe hemodynamic dysfunction - indeterminate or evolving cause0.00.00.00.00.00.00.0
Reintervention0.00.91.20.61.00.00.9
Explant0.00.91.20.61.00.00.9
PrimaryConfirm the Effectiveness of the Model 400 Avalus Valve With Regard to the Change of New York Heart Association (NYHA) Classification From Baseline Through 1 Year

At each timepoint, a minimum of 15 participants per valve size evaluated for change in New York Heart Association (NYHA) functional classification from baseline to 1 year post-procedure. Measure Description: Cardiac Disease with Functional Classes (lower value is more desirable than higher value) I - No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation or shortness of breath. II - Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, shortness of breath or chest pain. III - Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, shortness of breath or chest pain. IV - Symptoms of heart failure at rest. Any physical activity causes further discomfort.

Time frame:
Discharge (up to 30 days), 3-6 months, and 1 year post-implant
Reported as:
Count of participants · Participants
Confirm the Effectiveness of the Model 400 Avalus Valve With Regard to the Change of New York Heart Association (NYHA) Classification From Baseline Through 1 Year
ParticipantsMedtronic Avalus Valve 19mmMedtronic Avalus Valve 21mmMedtronic Avalus Valve 23mmMedtronic Avalus Valve 25mmMedtronic Avalus Valve 27mmMedtronic Avalus Valve 29mmMedtronic Avalus Valve (17mm - 29mm)
Discharge up to 30 days — Improved 3 Classes0052209
Discharge up to 30 days — Improved 2 Classes51430279186
Discharge up to 30 days — Improved 1 Class21831311082612382
Discharge up to 30 days — No Change1261118116237337
Discharge up to 30 days — Worsened 1 Class015161810362
Discharge up to 30 days — Worsened 2 Classes0121004
Discharge up to 30 days — Worsened 3 Classes0000000
3-6 Months — Improved 3 Classes01461012
3-6 Months — Improved 2 Classes155110382274282
3-6 Months — Improved 1 Class20971871644313525
3-6 Months — No Change5477679254236
3-6 Months — Worsened 1 Class02951118
3-6 Months — Worsened 2 Classes0000000
3-6 Months — Worsened 3 Classes0000000
1 Year — Improved 3 Classes01660013
1 Year — Improved 2 Classes136010579274289
1 Year — Improved 1 Class16831761614010486
1 Year — No Change8477670263230
1 Year — Worsened 1 Class05660017
1 Year — Worsened 2 Classes0000000
1 Year — Worsened 3 Classes0000000
PrimaryConfirm the Effectiveness of the Model 400 Avalus Valve With Regard to Effective Orifice Area Through 1 Year Post-procedure

A minimum of 15 participants per valve size evaluated by transthoracic echocardiography technique and assessed by an independent core laboratory. The effective orifice area (EOA) is measured as the minimal cross-sectional area of the blood flow downstream of the aortic valve.

Time frame:
Discharge (up to 30 days), 3-6 months, 1 year post-implant
Reported as:
Mean · cm^2
Confirm the Effectiveness of the Model 400 Avalus Valve With Regard to Effective Orifice Area Through 1 Year Post-procedure
cm^2Medtronic Avalus Valve 19mmMedtronic Avalus Valve 21mmMedtronic Avalus Valve 23mmMedtronic Avalus Valve 25mmMedtronic Avalus Valve 27mmMedtronic Avalus Valve 29mmMedtronic Avalus Valve (17mm - 29mm)
Discharge (up to 30 days)1.23 ± 0.241.35 ± 0.301.59 ± 0.341.68 ± 0.371.88 ± 0.422.29 ± 0.681.60 ± 0.40
3-6 Months1.22 ± 0.271.30 ± 0.261.54 ± 0.301.66 ± 0.321.89 ± 0.422.51 ± 0.711.57 ± 0.39
1 Year1.09 ± 0.231.26 ± 0.251.48 ± 0.331.60 ± 0.341.76 ± 0.352.42 ± 0.591.50 ± 0.38
PrimaryConfirm the Effectiveness of the Model 400 Avalus Valve With Regard to the Effective Orifice Area Index (EOAI) Through 1 Year Post-implant

A minimum of 15 participants per valve size evaluated by transthoracic echocardiography technique and assessed by an independent core laboratory for effective orifice area index (EOAI = EOA/BSA) Effective orifice area index is equal to the effective orifice area (EOA) in cm\^2 divided by body surface area (BSA) in m\^2. The achievement criterion for the effective orifice area index (EOAI) is defined to be ≥0.6 cm\^2/m\^2 12 months after the procedure. This criterion is in accordance with the definition of severe aortic stenosis in the American College of Cardiology (ACC) / American Heart Association (AHA) guidelines for the management of valvular heart disease.

Time frame:
Discharge (up to 30 days), 3-6 months, and 1 year post-implant
Reported as:
Mean · cm^2/m^2
Confirm the Effectiveness of the Model 400 Avalus Valve With Regard to the Effective Orifice Area Index (EOAI) Through 1 Year Post-implant
cm^2/m^2Medtronic Avalus Valve 19mmMedtronic Avalus Valve 21mmMedtronic Avalus Valve 23mmMedtronic Avalus Valve 25mmMedtronic Avalus Valve 27mmMedtronic Avalus Valve 29mmMedtronic Avalus Valve (17mm - 29mm)
Discharge (up to 30 days)0.71 ± 0.160.74 ± 0.180.81 ± 0.200.81 ± 0.190.89 ± 0.231.07 ± 0.30.81 ± 0.20
3-6 Months0.71 ± 0.170.72 ± 0.160.79 ± 0.170.81 ± 0.170.90 ± 0.221.16 ± 0.310.80 ± 0.19
1 Year0.63 ± 0.140.70 ± 0.150.76 ± 0.180.78 ± 0.170.82 ± 0.171.14 ± 0.280.76 ± 0.18
PrimaryConfirm the Effectiveness of the Model 400 Avalus Valve With Regard to the Peak Pressure Gradient (mmHg) From Discharge up to 1 Year

A minimum of 15 participants per valve size evaluated by transthoracic echocardiography technique and assessed by an independent core laboratory. The peak pressure gradient is the maximum value measured of flow of blood through the aortic valve as measured in millimeters of mercury.

Time frame:
Measured at discharge (up to 30 days), 3-6 months, and 1 year post-implant
Reported as:
Mean · mmHg
Confirm the Effectiveness of the Model 400 Avalus Valve With Regard to the Peak Pressure Gradient (mmHg) From Discharge up to 1 Year
mmHgMedtronic Avalus Valve 19mmMedtronic Avalus Valve 21mmMedtronic Avalus Valve 23mmMedtronic Avalus Valve 25mmMedtronic Avalus Valve 27mmMedtronic Avalus Valve 29mmMedtronic Avalus Valve (17mm - 29mm)
Discharge (up to 30 days)32.2 ± 9.728.0 ± 9.223.6 ± 8.022.4 ± 6.819.6 ± 6.816.2 ± 6.323.9 ± 8.4
3-6 Months27.2 ± 6.726.3 ± 8.621.6 ± 6.821.1 ± 7.217.7 ± 5.914.7 ± 6.322.1 ± 7.7
1 Year30.4 ± 8.227.8 ± 9.423.1 ± 7.522.0 ± 7.319.0 ± 6.718.1 ± 6.523.5 ± 8.3
PrimaryConfirm the Effectiveness of the Model 400 Avalus Valve With Regard to Mean Pressure Gradient (mmHg) Through 1 Year Post-implant

A minimum of 15 participants per valve size evaluated by transthoracic echocardiography technique and will be assessed by an independent core laboratory. The mean pressure gradient is the average flow of blood through the aortic valve measured in millimeters of mercury.

Time frame:
Discharge (up to 30 days), 3-6 months, and 1 year post-implant
Reported as:
Mean · mmHg
Confirm the Effectiveness of the Model 400 Avalus Valve With Regard to Mean Pressure Gradient (mmHg) Through 1 Year Post-implant
mmHgMedtronic Avalus Valve 19mmMedtronic Avalus Valve 21mmMedtronic Avalus Valve 23mmMedtronic Avalus Valve 25mmMedtronic Avalus Valve 27mmMedtronic Avalus Valve 29mmMedtronic Avalus Valve (17mm - 29mm)
Discharge (up to 30 days)18.2 ± 6.115.2 ± 4.912.9 ± 4.512.4 ± 3.910.7 ± 3.88.8 ± 3.513.1 ± 4.7
3-6 Months15.4 ± 4.414.2 ± 4.611.7 ± 3.711.3 ± 3.79.6 ± 3.37.9 ± 3.611.9 ± 4.1
1 Year17.1 ± 5.015.1 ± 5.312.3 ± 4.011.9 ± 4.010.1 ± 3.710.2 ± 3.512.7 ± 4.6
PrimaryConfirm the Effectiveness of the Model 400 Avalus Valve With Regard to Performance Index (L/Min) Through 1 Year Post-implant

A minimum of 15 participants per valve size will have performance index (L/Min) measured by transthoracic echocardiography technique and will be assessed by an independent core laboratory. The performance index is the measurement of the effective orifice area divided by the native orifice area.

Time frame:
Discharge (up to 30 days), 3-6 months, and 1 year post-implant
Reported as:
Mean · L/min
Confirm the Effectiveness of the Model 400 Avalus Valve With Regard to Performance Index (L/Min) Through 1 Year Post-implant
L/minMedtronic Avalus Valve 19mmMedtronic Avalus Valve 21mmMedtronic Avalus Valve 23mmMedtronic Avalus Valve 25mmMedtronic Avalus Valve 27mmMedtronic Avalus Valve 29mmMedtronic Avalus Valve (17mm - 29mm)
Discharge (up to 30 days)0.5 ± 0.10.5 ± 0.10.4 ± 0.10.4 ± 0.10.4 ± 0.10.4 ± 0.10.4 ± 0.1
3-6 Months0.5 ± 0.10.4 ± 0.10.4 ± 0.10.4 ± 0.10.4 ± 0.10.4 ± 0.10.4 ± 0.1
1 Year0.5 ± 0.10.4 ± 0.10.4 ± 0.10.4 ± 0.10.3 ± 0.10.4 ± 0.10.4 ± 0.1
PrimaryConfirm the Effectiveness of the Model 400 Avalus Valve With Regard to Cardiac Output (L/Min) Through 1 Year Post-implant

Cardiac output is the amount of blood pumped by the heart per minute. A minimum of 15 participants per valve size were evaluated for this outcome measure by transthoracic echocardiography technique and assessed by an independent core laboratory.

Time frame:
Discharge (up to 30 days), 3-6 months, and 1 year post-implant
Reported as:
Mean · L/min
Confirm the Effectiveness of the Model 400 Avalus Valve With Regard to Cardiac Output (L/Min) Through 1 Year Post-implant
L/minMedtronic Avalus Valve 19mmMedtronic Avalus Valve 21mmMedtronic Avalus Valve 23mmMedtronic Avalus Valve 25mmMedtronic Avalus Valve 27mmMedtronic Avalus Valve 29mmMedtronic Avalus Valve (17mm - 29mm)
Discharge (up to 30 days)5.0 ± 1.04.9 ± 1.25.1 ± 1.35.2 ± 1.25.3 ± 1.45.2 ± 1.25.1 ± 1.3
3-6 Months4.6 ± 1.14.5 ± 0.94.8 ± 1.04.9 ± 1.14.9 ± 1.25.8 ± 1.74.8 ± 1.1
1 Year4.3 ± 1.04.5 ± 1.14.7 ± 1.14.9 ± 1.24.8 ± 1.06.4 ± 2.04.7 ± 1.2
PrimaryConfirm the Effectiveness of the Model 400 Avalus Valve With Regard to Cardiac Index (L/Min/m^2) Through 1 Year Post-implant

A minimum of 15 participants per valve size evaluated by transthoracic echocardiography technique and will be assessed by an independent core laboratory. The cardiac index is an assessment of the cardiac output based on a patient's size measured by dividing the cardiac output by the patient's body's surface area.

Time frame:
Discharge (up to 30 days), 3-6 months, and 1 year post-implant
Reported as:
Mean · L/min/m^2
Confirm the Effectiveness of the Model 400 Avalus Valve With Regard to Cardiac Index (L/Min/m^2) Through 1 Year Post-implant
L/min/m^2Medtronic Avalus Valve 19mmMedtronic Avalus Valve 21mmMedtronic Avalus Valve 23mmMedtronic Avalus Valve 25mmMedtronic Avalus Valve 27mmMedtronic Avalus Valve 29mmMedtronic Avalus Valve (17mm - 29mm)
Discharge (up to 30 days)2.9 ± 0.72.7 ± 0.72.6 ± 0.72.5 ± 0.62.5 ± 0.72.4 ± 0.62.6 ± 0.7
3-6 Months2.7 ± 0.72.5 ± 0.52.4 ± 0.52.4 ± 0.52.3 ± 0.62.7 ± 0.72.4 ± 0.5
1 Year2.5 ± 0.52.5 ± 0.62.4 ± 0.52.4 ± 0.62.2 ± 0.43.0 ± 0.82.4 ± 0.6
SecondaryEvaluate the Safety of the Model 400 Avalus Valve With Regard to Valve-related Adverse Events and Death Annually Through 5 Years Post-implant

Safety of the valve is evaluated by the time-related incidence of valve-related adverse events and death. The following valve-related adverse events are evaluated in this study: Thromboembolism, Thrombosis, Hemorrhage, Paravalvular leak (PVL), Endocarditis, Hemolysis, Structural valve deterioration, Non-structural dysfunction, Reintervention, Explant, and Death. The Kaplan-Meier event rates will be used to summarize valve-related adverse events and death. The Kaplan-Meier rate and the corresponding 95% confidence interval will be presented for each visit interval.

Time frame:
Annually, at years 2, 3, 4, and 5 post-implant

Results for this outcome have not been posted.

SecondaryConfirm the Effectiveness of the Model 400 Avalus Valve With Regard to the Change of New York Heart Association (NYHA) Classification From Baseline Through 5 Years Post-implant

At each timepoint, participants were evaluated for change in New York Heart Association (NYHA) functional classification from baseline through 5 years post-procedure. Measure Description: Cardiac Disease with Functional Classes (lower value is more desirable than higher value) I - No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation or shortness of breath. II - Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, shortness of breath or chest pain. III - Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, shortness of breath or chest pain. IV - Symptoms of heart failure at rest. Any physical activity causes further discomfort.

Time frame:
Annually, at years 2, 3, 4, and 5 post-implant

Results for this outcome have not been posted.

SecondaryConfirm the Effectiveness of the Model 400 Avalus Valve With Regard to Effective Orifice Area Through 5 Years Post-procedure

Evaluated by transthoracic echocardiography technique and assessed by an independent core laboratory. The effective orifice area (EOA) is measured as the minimal cross-sectional area of the blood flow downstream of the aortic valve.

Time frame:
Annually, at years 2, 3, 4, and 5 post-implant

Results for this outcome have not been posted.

SecondaryConfirm the Effectiveness of the Model 400 Avalus Valve With Regard to the Effective Orifice Area Index (EOAI) Through 5 Years Post-implant

Evaluated by transthoracic echocardiography technique and assessed by an independent core laboratory for effective orifice area index (EOAI = EOA/BSA) Effective orifice area index is equal to the effective orifice area (EOA) in cm\^2 divided by body surface area (BSA) in m\^2. The achievement criterion for the effective orifice area index (EOAI) is defined to be ≥0.6 cm\^2/m\^2 12 months after the procedure. This criterion is in accordance with the definition of severe aortic stenosis in the American College of Cardiology (ACC) / American Heart Association (AHA) guidelines for the management of valvular heart disease.

Time frame:
Annually, at years 2, 3, 4, and 5 post-implant

Results for this outcome have not been posted.

SecondaryConfirm the Effectiveness of the Model 400 Avalus Valve With Regard to the Peak Pressure Gradient (mmHg) From Discharge up to 5 Years Post-implant

Evaluated by transthoracic echocardiography technique and assessed by an independent core laboratory. The peak pressure gradient is the maximum value measured of flow of blood through the aortic valve as measured in millimeters of mercury.

Time frame:
Annually, at years 2, 3, 4, and 5 post-implant

Results for this outcome have not been posted.

SecondaryConfirm the Effectiveness of the Model 400 Avalus Valve With Regard to Mean Pressure Gradient (mmHg) Through 5 Years Post-implant

Evaluated by transthoracic echocardiography technique and will be assessed by an independent core laboratory. The mean pressure gradient is the average flow of blood through the aortic valve measured in millimeters of mercury.

Time frame:
Annually, at years 2, 3, 4, and 5 post-implant

Results for this outcome have not been posted.

SecondaryConfirm the Effectiveness of the Model 400 Avalus Valve With Regard to Performance Index (L/Min) Through 5 Years Post-implant

Performance index (L/Min) measured by transthoracic echocardiography technique and will be assessed by an independent core laboratory. The performance index is the measurement of the effective orifice area divided by the native orifice area.

Time frame:
Annually, at years 2, 3, 4, and 5 post-implant

Results for this outcome have not been posted.

SecondaryConfirm the Effectiveness of the Model 400 Avalus Valve With Regard to Cardiac Output (L/Min) Through 5 Years Post-implant

Cardiac output is the amount of blood pumped by the heart per minute, evaluated by transthoracic echocardiography technique and assessed by an independent core laboratory.

Time frame:
Annually, at years 2, 3, 4, and 5 post-implant

Results for this outcome have not been posted.

SecondaryConfirm the Effectiveness of the Model 400 Avalus Valve With Regard to Cardiac Index (L/Min/m^2) Through 5 Years Post-implant

Evaluated by transthoracic echocardiography technique and will be assessed by an independent core laboratory. The cardiac index is an assessment of the cardiac output based on a patient's size measured by dividing the cardiac output by the patient's body's surface area.

Time frame:
Annually, at years 2, 3, 4, and 5 post-implant

Results for this outcome have not been posted.

Other pre-specifiedEvaluate the Safety of the Model 400 Avalus Valve With Regard to Valve-related Adverse Events and Death at 1 Year Post-implant (Remaining Data From 29mm Valve Participants Not Required for Meeting Primary Outcomes)

Safety of the valve is evaluated by the time-related incidence of valve-related adverse events and death. The following valve-related adverse events are evaluated in this study: Thromboembolism, Thrombosis, Hemorrhage, Paravalvular leak (PVL), Endocarditis, Hemolysis, Structural valve deterioration, Non-structural dysfunction, Reintervention, Explant, and Death. A minimum of 15 participants per valve size are evaluated. The Kaplan-Meier event rates will be used to summarize valve-related adverse events and death. The Kaplan-Meier rate and the corresponding 95% confidence interval will be presented for each visit interval.

Time frame:
1 year post-implant

Results for this outcome have not been posted.

Other pre-specifiedConfirm the Effectiveness of the Model 400 Avalus Valve With Regard to the Change of New York Heart Association (NYHA) Classification From Baseline Through 1 Year (Remaining Data From 29mm Valve Participants Not Required for Meeting Primary Outcomes)

Participants evaluated for change in New York Heart Association (NYHA) functional classification from baseline to 1 year post-procedure. Measure Description: Cardiac Disease with Functional Classes (lower value is more desirable than higher value) I - No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation or shortness of breath. II - Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, shortness of breath or chest pain. III - Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, shortness of breath or chest pain. IV - Symptoms of heart failure at rest. Any physical activity causes further discomfort.

Time frame:
3-6 months and 1 year post-implant

Results for this outcome have not been posted.

Other pre-specifiedConfirm the Effectiveness of the Model 400 Avalus Valve With Regard to Effective Orifice Area Through 1 Year Post-procedure (Remaining Data From 29mm Valve Participants Not Required for Meeting Primary Outcomes)

Evaluated by transthoracic echocardiography technique and assessed by an independent core laboratory. The effective orifice area (EOA) is measured as the minimal cross-sectional area of the blood flow downstream of the aortic valve.

Time frame:
3-6 months, 1 year post-implant

Results for this outcome have not been posted.

Other pre-specifiedConfirm the Effectiveness of the Model 400 Avalus Valve With Regard to the Effective Orifice Area Index (EOAI) Through 1 Year Post-implant (Remaining Data From 29mm Valve Participants Not Required for Meeting Primary Outcomes)

Evaluated by transthoracic echocardiography technique and assessed by an independent core laboratory for effective orifice area index (EOAI = EOA/BSA) Effective orifice area index is equal to the effective orifice area (EOA) in cm\^2 divided by body surface area (BSA) in m\^2. The achievement criterion for the effective orifice area index (EOAI) is defined to be ≥0.6 cm\^2/m\^2 12 months after the procedure. This criterion is in accordance with the definition of severe aortic stenosis in the American College of Cardiology (ACC) / American Heart Association (AHA) guidelines for the management of valvular heart disease.

Time frame:
3-6 months, and 1 year post-implant

Results for this outcome have not been posted.

Other pre-specifiedConfirm the Effectiveness of the Model 400 Avalus Valve With Regard to the Peak Pressure Gradient (mmHg) From Discharge up to 1 Year (Remaining Data From 29mm Valve Participants Not Required for Meeting Primary Outcomes)

Evaluated by transthoracic echocardiography technique and assessed by an independent core laboratory. The peak pressure gradient is the maximum value measured of flow of blood through the aortic valve as measured in millimeters of mercury.

Time frame:
3-6 months, and 1 year post-implant

Results for this outcome have not been posted.

Other pre-specifiedConfirm the Effectiveness of the Model 400 Avalus Valve With Regard to Mean Pressure Gradient (mmHg) Through 1 Year Post-implant (Remaining Data From 29mm Valve Participants Not Required for Meeting Primary Outcomes)

Evaluated by transthoracic echocardiography technique and will be assessed by an independent core laboratory. The mean pressure gradient is the average flow of blood through the aortic valve measured in millimeters of mercury.

Time frame:
3-6 months, and 1 year post-implant

Results for this outcome have not been posted.

Other pre-specifiedConfirm the Effectiveness of the Model 400 Avalus Valve With Regard to Performance Index (L/Min) Through 1 Year Post-implant (Remaining Data From 29mm Valve Participants Not Required for Meeting Primary Outcomes)

Performance index (L/Min) measured by transthoracic echocardiography technique and will be assessed by an independent core laboratory. The performance index is the measurement of the effective orifice area divided by the native orifice area.

Time frame:
3-6 months, and 1 year post-implant

Results for this outcome have not been posted.

Other pre-specifiedConfirm the Effectiveness of the Model 400 Avalus Valve With Regard to Cardiac Output (L/Min) Through 1 Year Post-implant (Remaining Data From 29mm Valve Participants Not Required for Meeting Primary Outcomes)

Cardiac output is the amount of blood pumped by the heart per minute. Evaluated by transthoracic echocardiography technique and assessed by an independent core laboratory.

Time frame:
3-6 months, and 1 year post-implant

Results for this outcome have not been posted.

Other pre-specifiedConfirm the Effectiveness of the Model 400 Avalus Valve With Regard to Cardiac Index (L/Min/m^2) Through 1 Year Post-implant (Remaining Data From 29mm Valve Participants Not Required for Meeting Primary Outcomes)

Evaluated by transthoracic echocardiography technique and will be assessed by an independent core laboratory. The cardiac index is an assessment of the cardiac output based on a patient's size measured by dividing the cardiac output by the patient's body's surface area.

Time frame:
3-6 months, and 1 year post-implant

Results for this outcome have not been posted.

Other pre-specifiedConfirm the Effectiveness of the Model 400 Avalus Valve by Clinically Acceptable Hemodynamic Performance From Years 6 Through 12 Post-implant.

Long-term follow-up clinically acceptable hemodynamic performance defined as freedom from surgical explant and/or percutaneous valve-in-valve reintervention due to structural valve deterioration

Time frame:
Annually, years 6-12 post-implant

Results for this outcome have not been posted.

Other pre-specifiedConfirm the Effectiveness of the Model 400 Avalus Valve From Years 6 - 12 Post-implant by Freedom From Valve-related Death
Time frame:
Annually, years 6 though 12 post-implant

Results for this outcome have not been posted.

Other pre-specifiedConfirm the Effectiveness of the Model 400 Avalus Valve From Years 6 - 12 Post-implant by Freedom From All-cause Mortality

For time-to-event outcomes, Kaplan-Meier (actuarial) analysis of the event-free rate performed annually through twelve years.

Time frame:
Annually, years 6 though 12 post-implant

Results for this outcome have not been posted.

Other pre-specifiedConfirm the Effectiveness of the Model 400 Avalus Valve From Years 6 - 12 Post-implant by Change in NYHA Functional Classification Status From Baseline
Time frame:
Annually, years 6 though 12 post-implant

Results for this outcome have not been posted.

Other pre-specifiedConfirm the Effectiveness of the Model 400 Avalus Valve With Regard to Effective Orifice Area Through 12 Years Post-procedure

Evaluated by transthoracic echocardiography technique and assessed by an independent core laboratory. The effective orifice area (EOA) is measured as the minimal cross-sectional area of the blood flow downstream of the aortic valve.

Time frame:
Annually, years 6 though 12 post-implant

Results for this outcome have not been posted.

Other pre-specifiedConfirm the Effectiveness of the Model 400 Avalus Valve With Regard to the Effective Orifice Area Index (EOAI) Through 12 Years Post-implant

Evaluated by transthoracic echocardiography technique and assessed by an independent core laboratory for effective orifice area index (EOAI = EOA/BSA) Effective orifice area index is equal to the effective orifice area (EOA) in cm\^2 divided by body surface area (BSA) in m\^2. The achievement criterion for the effective orifice area index (EOAI) is defined to be ≥0.6 cm\^2/m\^2 12 months after the procedure. This criterion is in accordance with the definition of severe aortic stenosis in the American College of Cardiology (ACC) / American Heart Association (AHA) guidelines for the management of valvular heart disease.

Time frame:
Annually, years 6 though 12 post-implant

Results for this outcome have not been posted.

Other pre-specifiedConfirm the Effectiveness of the Model 400 Avalus Valve With Regard to the Peak Pressure Gradient (mmHg) up to 12 Years Post-implant

Evaluated by transthoracic echocardiography technique and assessed by an independent core laboratory. The peak pressure gradient is the maximum value measured of flow of blood through the aortic valve as measured in millimeters of mercury.

Time frame:
Annually, years 6 though 12 post-implant

Results for this outcome have not been posted.

Other pre-specifiedConfirm the Effectiveness of the Model 400 Avalus Valve With Regard to Mean Pressure Gradient (mmHg) Through 12 Years Post-implant

Evaluated by transthoracic echocardiography technique and will be assessed by an independent core laboratory. The mean pressure gradient is the average flow of blood through the aortic valve measured in millimeters of mercury.

Time frame:
Annually, years 6 though 12 post-implant

Results for this outcome have not been posted.

Other pre-specifiedConfirm the Effectiveness of the Model 400 Avalus Valve With Regard to Performance Index (L/Min) Through 12 Years Post-implant

Performance index (L/Min) measured by transthoracic echocardiography technique and will be assessed by an independent core laboratory. The performance index is the measurement of the effective orifice area divided by the native orifice area.

Time frame:
Annually, years 6 though 12 post-implant

Results for this outcome have not been posted.

Other pre-specifiedConfirm the Effectiveness of the Model 400 Avalus Valve With Regard to Cardiac Output (L/Min) Through 12 Years Post-implant

Cardiac output is the amount of blood pumped by the heart per minute. Evaluated by transthoracic echocardiography technique and assessed by an independent core laboratory.

Time frame:
Annually, years 6 though 12 post-implant

Results for this outcome have not been posted.

Other pre-specifiedConfirm the Effectiveness of the Model 400 Avalus Valve With Regard to Cardiac Index (L/Min/m^2) Through 12 Years Post-implant

Evaluated by transthoracic echocardiography technique and will be assessed by an independent core laboratory. The cardiac index is an assessment of the cardiac output based on a patient's size measured by dividing the cardiac output by the patient's body's surface area.

Time frame:
Annually, years 6 though 12 post-implant

Results for this outcome have not been posted.

Adverse events

Collected over Site reported adverse events and serious adverse events data collected from implant through 1 year.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Medtronic Avalus Valve (All Valve Sizes)170/1,132 (15%)638/1,132 (56.4%)1,105/1,132 (97.6%)
Most frequent serious events
Showing 10 of 219
Most frequent serious events
EventMedtronic Avalus Valve (All Valve Sizes)
Supraventricular ArrhythmiasCardiac disorders146/1132
Pneumothorax And Pleural Effusions NecRespiratory, thoracic and mediastinal disorders111/1132
Anaemias NecBlood and lymphatic system disorders98/1132
Non-Site Specific Procedural ComplicationsInjury, poisoning and procedural complications55/1132
Cardiac Conduction DisordersCardiac disorders49/1132
Pericardial Disorders NecCardiac disorders49/1132
Heart Failures NecCardiac disorders43/1132
Respiratory Failures (Excl Neonatal)Respiratory, thoracic and mediastinal disorders40/1132
Renal Failure And ImpairmentRenal and urinary disorders38/1132
Central Nervous System Haemorrhages And Cerebrovascular AccidentsNervous system disorders37/1132
Most frequent other events
Showing 10 of 33
Most frequent other events
EventMedtronic Avalus Valve (All Valve Sizes)
Supraventricular ArrhythmiasCardiac disorders674/1132
Anaemias NecBlood and lymphatic system disorders420/1132
Cardiac Conduction DisordersCardiac disorders396/1132
Pneumothorax And Pleural Effusions NecRespiratory, thoracic and mediastinal disorders387/1132
Non-Site Specific Procedural ComplicationsInjury, poisoning and procedural complications276/1132
ThrombocytopeniasBlood and lymphatic system disorders255/1132
Vascular Hypotensive DisordersVascular disorders225/1132
Hyperglycaemic Conditions NecMetabolism and nutrition disorders220/1132
Oedema NecGeneral disorders183/1132
Pericardial Disorders NecCardiac disorders167/1132

Baseline characteristics

Age, Continuous
Age, Continuous(years)Medtronic Model 400 Avalus Bioprosthetic Aortic Valve
Mean70.1 ± 8.9
Sex: Female, Male
Sex: Female, Male(Participants)Medtronic Model 400 Avalus Bioprosthetic Aortic Valve
Female278
Male854
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Medtronic Model 400 Avalus Bioprosthetic Aortic Valve
Hispanic or Latino19
Not Hispanic or Latino638
Unknown or Not Reported475
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Medtronic Model 400 Avalus Bioprosthetic Aortic Valve
American Indian or Alaska Native0
Asian11
Native Hawaiian or Other Pacific Islander0
Black or African American9
White636
More than one race0
Unknown or Not Reported476
Region of Enrollment
Region of Enrollment(participants)Medtronic Model 400 Avalus Bioprosthetic Aortic Valve
Canada268
Europe475
United States389
New York Heart Association (NYHA) Classification
New York Heart Association (NYHA) Classification(Participants)Medtronic Model 400 Avalus Bioprosthetic Aortic Valve
NYHA Class I126
NYHA Class II533
NYHA Class III451
NYHA Class IV22
08

Study locations

38 sites
09

References and documents

Publications

  • Velders BJJ, Vriesendorp MD, Weissman NJ, Sabik JF 3rd, Reardon MJ, Dagenais F, Moront MG, Rao V, Fukuhara S, Gunzinger R, van Leeuwen WJ, Brown WM, Groenwold RHH, Klautz RJM, Asch FM. Core Laboratory Versus Center-Reported Echocardiographic Assessment of the Native and Bioprosthetic Aortic Valve. Echocardiography. 2024 Dec;41(12):e70047. doi: 10.1111/echo.70047. PubMed 39624936 ↗
  • Klautz RJM, Rao V, Reardon MJ, Deeb GM, Dagenais F, Moront MG, Little SH, Labrousse L, Patel HJ, Ito S, Li S, Sabik JF 3rd, Oh JK. Examining the typical hemodynamic performance of nearly 3000 modern surgical aortic bioprostheses. Eur J Cardiothorac Surg. 2024 May 3;65(5):ezae122. doi: 10.1093/ejcts/ezae122. PubMed 38710669 ↗
  • Velders BJJ, Vriesendorp MD, De Lind Van Wijngaarden RAF, Rao V, Reardon MJ, Shrestha M, Chu MWA, Sabik JF 3rd, Liu F, Klautz RJM. Perioperative care differences of surgical aortic valve replacement between North America and Europe. Heart. 2023 Jun 26;109(14):1106-1112. doi: 10.1136/heartjnl-2023-322350. PubMed 36963820 ↗
  • Klautz RJM, Kappetein AP, Lange R, Dagenais F, Labrousse L, Bapat V, Moront M, Misfeld M, Zeng C, Sabik Iii JF; PERIGON Investigators. Safety, effectiveness and haemodynamic performance of a new stented aortic valve bioprosthesis. Eur J Cardiothorac Surg. 2017 Sep 1;52(3):425-431. doi: 10.1093/ejcts/ezx066. PubMed 28475690 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2014 to primary completion in Apr 2023, 107 months.

Results were first posted in Jun 2024, 1 year 1 month after primary completion.

Of 111 industry-sponsored interventional studies with no phase under Aortic Valve Stenosis, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 54. This study's 107 months is above that.

Counting every sponsor, half of 288 studies reached it within 33 months; a quarter within 18 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2014
First posted
Mar 17, 2014
StartActual
May 12, 2014
Primary completionActual
Apr 17, 2023
CompletionEst.
Dec 31, 2035
Results first posted
Jun 4, 2024
Last update
Apr 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02088554
Collaborators
Medtronic
Responsible party
Sponsor
First posted
Mar 17, 2014
Start date
May 12, 2014
Primary completion
Apr 17, 2023
Completion
Dec 31, 2035 (estimated)
Results posted
Jun 4, 2024
Last update
Apr 29, 2026

Study contacts

Joseph Sabik, MD
principal investigator · University Hospital Cleveland Medical Center (Not a recruiting site)
Prof. Dr. Robert Johannes Menno Klautz, MD
principal investigator · Leiden University Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion